Medtronic Acquires Angiolink

In a transaction that will enlarge its vascular closure portfolio, Medtronic, Inc. (Minneapolis, MN, USA) has acquired Angiolink Corp. (Taunton, MA, USA). Financial terms were not disclosed.

Angiolink is focused on developing closure solutions for vascular procedures. The company's Expanding Vascular Stapling (EVS) closure system is designed to close the femoral artery access site after vascular procedures, such as angiography or stenting. EVS provides safe and effective mechanical closure of arterial puncture sites without disturbing the lumen of the targeted vessel. The system, designed to quickly stop site bleeding, applies a titanium staple that stabilizes and closes the artery. EVS has been cleared by the U.S. Food and Drug Administration (FDA).

Vascular closure is an emerging market and complementary to the coronary and peripheral vascular businesses of Medtronic. The 2004 vascular closure market is estimated to be about U.S.$500 million and is expected to grow to more than $1 billion by 2009.

"What I found particularly compelling from the clinical trial experience was that I can now safely and effectively close patients independent of vessel anatomy, access site location, or the presence of peripheral vascular disease,” commented principal investigator, Gary Ansel, M.D., of the Riverside Methodist Medical Center in Columbus (OH, USA).





Related Links:
Medtronic
Angiolink